Zynerba Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company best known to market participants as a development-stage specialty pharma name, historically associated with SEC filings and insider-transaction reporting. The company was incorporated in Delaware in 2007 as AllTranz, Inc. and later changed its name to Zynerba Pharmaceuticals, Inc. in 2014. Its headquarters are in the United States, and its shares were listed on the U.S. market, specifically NASDAQ, which places the company within the highly regulated American public-equity and biotech ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837019010074/zyne-20190930x10q.htm?utm_source=openai)) Operationally, Zynerba has been a focused clinical-stage company rather than a diversified pharmaceutical platform. Its core thesis has centered on pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company’s lead development efforts have historically targeted Fragile X syndrome (FXS) and 22q11.2 deletion syndrome, while earlier disclosures also referenced autism spectrum disorder and a group of rare epilepsies. In SEC disclosures, Zynerba described itself as prioritizing resources on FXS and 22q11.2, both of which have no approved products. That makes the company a classic high-risk, high-upside biotech story: concentrated pipeline, meaningful unmet medical need, but substantial clinical, regulatory, and financing risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837023004765/zyne-20221231x10k.htm?utm_source=openai)) A key element of Zynerba’s positioning has been its transdermal delivery approach. In theory, a skin-applied cannabinoid formulation can offer differentiated convenience, steadier exposure, and potentially better tolerability than some oral approaches. That said, the commercial moat depends entirely on proof of efficacy, safety, manufacturability, and regulatory approval—none of which is guaranteed in orphan neurology. Zynerba has also highlighted FDA orphan-drug designations and European Commission orphan status for cannabidiol in FXS and 22q11.2 deletion syndrome, along with FDA Fast Track designation for behavioral symptoms associated with FXS. These designations can be strategically valuable, but they do not substitute for successful late-stage data or eventual commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837023004765/zyne-20221231x10k.htm?utm_source=openai)) From a competitive standpoint, Zynerba operates in a narrow but crowded scientific race: rare neuropsychiatric and neurologic diseases attract biotech, academic, and pharmaceutical competitors pursuing gene therapy, small molecules, and other precision approaches. Zynerba’s differentiation has been the cannabinoid/transdermal angle, but investor attention has primarily been driven by binary clinical milestones, cash runway, and capital-market events rather than by revenue generation. Recent SEC materials continue to characterize the company as a clinical-stage specialty pharmaceutical enterprise, underscoring its dependence on development outcomes and financing capacity. For international investors, especially those in Europe analyzing U.S.-listed healthcare small caps, Zynerba exemplifies the risk profile of NASDAQ biotech: concentrated pipeline exposure, heavy regulatory dependence, and a value proposition tied to future data rather than current sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000110465923048382/tm2311178d2_ars.pdf?utm_source=openai))